医学
乳腺癌
全身给药
癌症
阿霉素
乳腺
乳腺肿瘤
全身疗法
内科学
肿瘤科
化疗
毒性
病理
癌症研究
体内
生物
生物技术
作者
Satoshi Murata,Scott L. Kominsky,Mustafa Vali,Zhe Zhang,Elizabeth Garrett‐Mayer,Dorian Korz,David L. Huso,Sharyn D. Baker,James Barber,Elizabeth M. Jaffee,R. Todd Reilly,Saraswati Sukumar
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2006-01-15
卷期号:66 (2): 638-645
被引量:89
标识
DOI:10.1158/0008-5472.can-05-4329
摘要
Abstract In cancer patients and in those at high risk, systemic exposure to agents for therapy or prevention is accompanied by undesirable side effects. We hypothesized that it is possible to prevent and treat breast cancer by introducing anticancer agents into the mammary ductal network. Here, we show the efficacy of intraductally administered anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatment of breast cancer using the rat N-methyl-N′-nitrosourea–induced and spontaneous HER-2/neu transgenic mouse (neu-N) models of breast cancer. Intraductal administration of PLD to neu-N mice caused regression of established tumors and prevented tumor development more effectively than i.v. injection (P < 0.0001). Intraductal administration resulted in lower circulating levels of PLD compared with i.v. administration, with no evidence of systemic toxicity or long-term histopathologic changes in the mammary gland. Compared with systemic administration, intraductal injection provides direct access to breast lesions with higher local and lower systemic drug exposure. These studies suggest that this approach has potential for application to prevention and neoadjuvant therapy of early breast cancer. (Cancer Res 2006; 66(2): 638-45)
科研通智能强力驱动
Strongly Powered by AbleSci AI